Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing
William Hope(University of Liverpool), Thomas J. Walsh(Cornell University), Tawanda Gumbo(Raptamer Discovery Group (United States)), Cindy L. Schwartz(Brown University), Donald N. Buell(Astellas Pharma (Japan)), George L. Drusano(University of Florida), Antonio Arrieta(Children's Hospital of Orange County), Nita L. Seibel(National Cancer Institute), James J. Keirns(Boehringer Ingelheim (United States)), Patricia M. Flynn(St. Jude Children's Research Hospital), Aziza Shad(Georgetown University), Edythe A. Albano(Office of the Director)
Cited by 110
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.6k
Chronic Health Conditions in Adult Survivors of Childhood Cancer
|New England Journal of Medicine|2006|3.6k
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k